Thursday, May 30, 2024
HomeWellnessDrugs and MedicationsDoes Canagliflozin Benefit Heart Disease?

Does Canagliflozin Benefit Heart Disease?

Heart disease is an important co-morbidity in diabetes management. Researchers compared the cardiovascular safety data of canagliflozin with three other antidiabetic drug classes.

A new class of antidiabetic medications called sodium glucose co-transporter 2 inhibitors has shown cardiovascular benefits in patients with type 2 diabetes. This drug class works by blocking the re-absorption of glucose in the kidneys, thereby reducing blood glucose levels. Medications in this class include canagliflozin, dapagliflozin, and empagliflozin. Although maintaining glucose levels within an appropriate range is important in reducing the risk of developing complications, intensive glucose lowering and the use of certain antidiabetics have been associated with negative heart health outcomes.

An American study recently published in The British Medical Journal evaluated the cardiovascular safety outcomes of canagliflozin in comparison to DPP-4 inhibitors, GPL-1 agonists, and sulfonylureas. This population-based retrospective cohort study comprised of data collected from a healthcare database in the United States between April 2013 and September 2015. The study participants were adults with a type 2 diabetes diagnosis and had been started on canagliflozin, a DPP-4 inhibitor, GPL-1 agonist, or a sulfonylurea within the 30-month study period. The main outcomes measured were hospital admissions for heart failure and other measures of heart health including hospital admission for acute myocardial infarction, ischemic stroke, or hemorrhagic stroke.

Canagliflozin Lowered the Risk of Heart Failure

The results of the study showed that the participants who were on canagliflozin had a 30% to 49% lower risk of developing heart failure and had fewer hospital admissions for heart failure than the participants on the other antidiabetic medications. There was no significant difference in the risk of hospital admission for acute myocardial infarction, ischemic stroke, or hemorrhagic stroke among the four drug classes.

The study demonstrates the beneficial effects of canagliflozin on hospital admissions due to heart failure. It also notes that the potential benefits of this medication can be observed within the first six months of therapy. This study demonstrates the importance of this class of medications in managing cardiovascular outcomes in patients diagnosed with diabetes.

Written by Anuolu Bank-Oni, PharmD, CDE, BCGP

Reference: Patorno, E et al. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. BMJ 2018;360:k119



Please enter your comment!
Please enter your name here

Latest News and Articles


Stay Connected

Article of the month

Recognizing HIE: A Call for Advocacy

Have you heard of HIE? It’s the second leading cause of infant mortality and lifelong disability worldwide. 2-3 per 1,000 live births in high-income...

Joke Of The Day – May 30

Patient: Doc, please come to my home as soon as possible! My wife has appendicitis! Doctor: Don't worry. Two years ago I did surgery to...


error: Content is read-only and copy-protected.